Zombie Funds and Wind-Down: What Happens When a VC Fund Underperforms

The term "zombie fund" sounds dramatic, but for limited partners sitting on locked capital with no distributions in sight, it describes a very real — and increasingly common — problem in venture.

As the 2021–2022 vintage funds age into their eighth and ninth years with portfolios still marked at inflated valuations and exits nowhere on the horizon, the question of what happens to underperforming VC funds is moving from theoretical to urgent. Understanding the mechanics of zombie funds, wind-downs, and GP-LP negotiations is now essential knowledge for anyone deploying capital into the asset class.

What Is a Zombie Fund?

A zombie fund is a venture capital fund that is technically still alive — the legal entity exists, the GP is still collecting management fees — but is effectively dead in terms of its ability to return capital to LPs. The fund isn't generating meaningful distributions, isn't raising a successor fund, and isn't actively investing. It just... lingers.

The term has no precise legal definition, but practitioners generally apply it to funds that meet several criteria:

• Past their investment period (typically years 1–5 of a 10-year fund life)
• No realistic path to a successful exit for the majority of portfolio companies
• GP still collecting fees, often at reduced rates during the harvest period
• No successor fund raised, signaling the market has lost confidence in the manager
• Low or negative TVPI with a portfolio that hasn't been marked down to reflect reality

According to Preqin data, roughly 1,700 venture funds globally had been in operation for more than ten years as of 2023 without completing a full distribution cycle — a figure that's grown substantially since the 2021 boom minted hundreds of new managers who are now struggling to find exits.

How Funds Become Zombies

The path to zombie status usually isn't dramatic. It's a slow drift driven by a combination of market conditions, portfolio concentration, and GP inaction.

The Valuation Hangover

The 2020–2021 period saw extraordinary valuations at both entry and follow-on stages. Many funds marked their portfolios up aggressively based on paper gains from priced rounds — only to see those valuations stagnate or decline as the rate environment shifted in 2022. GPs who haven't written down these positions are sitting on portfolios with inflated NAVs that bear little relationship to liquidation value.

This creates a perverse incentive: so long as the reported TVPI stays above 1.0x on paper, GPs can argue the fund isn't a failure. The reality, once time-adjusted returns are factored in, often tells a different story. A fund that returns 1.1x gross over 12 years has delivered a deeply negative IRR once you account for the opportunity cost of capital.

The Follow-On Trap

Many zombie situations are exacerbated by follow-on investment strategies. GPs who deployed significant reserves into their best-performing companies during the boom are now watching those companies struggle to grow into their valuations. The follow-on capital is trapped alongside the initial investment, and the portfolio is more concentrated — and more exposed — than originally intended.

The Successor Fund Problem

One of the clearest signals that a fund is trending zombie is the failure to raise a successor vehicle. GPs typically begin fundraising for Fund II or Fund III around years 4–6 of their current fund. When that process stalls, they lose access to new management fees, which can reduce their incentive to actively manage the existing portfolio. Without the institutional infrastructure of a growing platform, the GP's attention often drifts — toward other employment, advisory work, or simply away from the portfolio.

The LP's Position: Limited Leverage, Real Pain

LPs in underperforming funds face a frustrating combination of contractual constraints and practical limitations. The limited partnership agreement (LPA) is typically written to protect GP authority over investment decisions and exit timing. LPs generally cannot force a GP to sell assets, wind down the fund, or return capital.

What LPs can do, depending on LPA terms:

• Vote to extend the fund life (or refuse to do so)
• Exercise no-fault removal of the GP if a supermajority threshold is met (commonly 75–80% of LP interests)
• Withhold consent for material amendments
• Seek secondary market solutions to exit their position

The no-fault removal clause sounds powerful, but it's rarely used in practice. The process is expensive, legally complex, and requires coordinating LPs who often have competing interests and different entry points. Institutional LPs with large positions have more leverage than smaller allocators, and getting a supermajority aligned is genuinely difficult.

The Secondary Market as an Escape Valve

For LPs who need liquidity, the secondary market has become an increasingly important tool — but it's a costly one in zombie situations. Stakes in underperforming funds trade at steep discounts, often 40–70% below reported NAV, and sometimes the bids simply don't come. Specialized secondary buyers like Lexington Partners, Coller Capital, and Harbourvest will look at distressed VC positions, but they need to see some residual value and a credible path to exits.

GP-led secondaries — where the GP engineers a transaction to provide LP liquidity while maintaining control of remaining assets — have grown significantly, but these structures are generally reserved for funds with quality assets worth preserving. A true zombie rarely attracts the interest needed to support a GP-led process.

Fund Extensions: Buying Time or Prolonging the Pain?

Most VC fund LPAs provide for a 10-year base term with optional one or two-year extensions, often requiring LP consent. Extensions have become commonplace — nearly 60% of funds from the 2013–2015 vintage had extended beyond their original term by 2023, according to industry estimates.

A fund extension is not inherently a sign of failure. Some extension requests are entirely legitimate:

• A portfolio company is 12–18 months from an IPO or strategic acquisition
• A single large position needs more time to mature
• Market conditions have temporarily closed exit windows for otherwise strong assets

The problem is when extensions become reflexive — requested not because there's a credible near-term exit, but because the GP hasn't found a buyer and isn't ready to recognize losses. LPs should scrutinize extension requests carefully and demand specificity: which assets are being held, why, and what concrete milestones will trigger a wind-down if not achieved.

What LPs Should Ask Before Approving an Extension

1. What is the current carrying value vs. estimated liquidation value of remaining assets?
2. What specific exit processes are underway or planned?
3. Is the GP willing to reduce or eliminate management fees during the extension period?
4. What is the timeline, and what triggers a formal wind-down if milestones aren't met?
5. Has the GP engaged a third-party advisor to assess residual portfolio value?

Fee concessions during extensions are increasingly expected. GPs who insist on maintaining full management fees while delivering no distributions are likely to face LP pushback — and damage to their long-term reputation in the market.

Wind-Down: What It Actually Looks Like

When a fund does reach the end of its life — whether through a scheduled expiration, GP-LP negotiation, or a formal wind-down process — the mechanics can be messy.

Distributing Remaining Assets

If portfolio companies haven't been sold, the fund may distribute shares in-kind to LPs rather than holding for a cash exit. In-kind distributions of illiquid private company stock are often unwelcome — LPs receive a position they may have no infrastructure to manage and can't easily sell.

For publicly traded positions resulting from IPOs, in-kind distributions are more manageable, but LPs still face lockup restrictions and market timing risk on liquidation.

Write-Offs and Final Accounting

Most wind-downs involve a final accounting in which remaining positions are either sold at whatever price the market will bear, written off entirely, or transferred to a continuation vehicle. The GP and LP both typically want a clean end to the relationship, which can motivate compromise — GPs sometimes agree to waive remaining carried interest or accept reduced fees in exchange for LP consent on a clean wind-down.

GP Obligations Post Wind-Down

Even after a fund is formally wound down, certain GP obligations survive: tax reporting, FOIA obligations for public pension LPs, and any litigation arising from the fund's operations. GPs who shut down their firms entirely need to ensure they've made adequate provisions for these tail obligations — which can linger for years.

What Fund Managers Can Do to Avoid Zombie Status

Prevention is far preferable to cure. Fund managers who want to avoid the zombie trap should build in discipline from day one:

• Underwrite exits conservatively — a portfolio company needs to be acquirable, not just theoretically IPO-able
• Communicate proactively with LPs when a position is struggling, rather than avoiding the conversation
• Reserve capital thoughtfully — follow-on reserves that double down on struggling positions accelerate zombie risk
• Engage secondary advisors early if the portfolio isn't tracking toward successful exits by year 7
• Be honest about fund performance in LP reporting — GPs who manage expectations down early preserve more credibility than those who maintain optimistic marks until the last possible moment

The Bigger Picture for the VC Ecosystem

Zombie funds are not just a problem for the LPs and GPs involved — they represent a systemic issue for the venture ecosystem. Capital locked in underperforming vehicles isn't recycled into new companies. Founder relationships are mismanaged or neglected. And the reputational damage from a zombie fund can effectively end a GP's ability to raise again.

As the 2021–2022 vintage cohort ages and the full picture of that era's excesses becomes clear, expect the zombie fund conversation to intensify. LPs who built robust monitoring frameworks and negotiated tight LPA protections will be better positioned. Those who didn't are likely learning expensive lessons right now.

Key Takeaways

• Zombie funds are funds that still exist legally but have no realistic path to meaningful LP returns
• The primary drivers are inflated entry valuations, failed successor fundraises, and GP inaction
• LPs have limited contractual leverage but can use secondary markets, extension negotiations, and no-fault removal as tools
• Fund extensions are legitimate in specific circumstances but should be granted with fee concessions and clear milestones
• Wind-downs involve in-kind distributions, final write-offs, and surviving GP obligations
• Prevention — through conservative underwriting, proactive communication, and honest reporting — is the best strategy for GPs